The 88 rating InvestorsObserver gives to Trillium Therapeutics Inc (TRIL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, TRILs 88 overall rating means the stock scores better than 88 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 88 would rank higher than 88 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Trillium Therapeutics Inc (TRIL) stock is trading at $4.23 as of 1:51 PM on Monday, Apr 6, an increase of $0.57, or 15.57% from the previous closing price of $3.66. The stock has traded between $3.76 and $4.31 so far today. Volume today is less active than usual. So far 1,151,186 shares have traded compared to average volume of 3,800,958 shares.

To see InvestorsObserver's Sentiment Score for Trillium Therapeutics Inc click here.

See the rest here:
Industry Breakdown: Where Does Trillium Therapeutics Inc (TRIL) Stock Fall in the Biotechnology Field? - InvestorsObserver